Blog & Insights
Expert perspectives on bioinformatics, drug discovery, scientific writing, and R&D strategy
Biomarkers Are Not Drug Targets, and Why That Distinction Costs the Industry Billions
Why conflating biomarkers with drug targets leads to failed trials and billions lost. A deep dive into causal cell-state pharmacology.
Biomarkers Are Not Drug Targets, and Why That Distinction Costs the Industry Billions
If one assumption has quietly cost pharmaceutical R&D more than any other in the past two decades, i...
Biomarkers Are Not Drug Targets, and Why That Distinction Costs the Industry Billions
Why conflating biomarkers with drug targets leads to failed trials and billions lost. A deep dive in...
AI as Tool vs AI as Inventor: Why the Distinction Will Decide the Next Decade of Patents
There are two versions of "AI in drug discovery" being marketed right now, and they are not the same...
PRISMA 2020 in Practice: Five Things Most Systematic Reviews Still Get Wrong
PRISMA 2020 has been the reference reporting standard for systematic reviews for several years. Most...
Search
Recent Posts
-
Biomarkers Are Not Drug Targets, and Why That Distinction Costs the Industry Billions
June 06, 2026
-
AI as Tool vs AI as Inventor: Why the Distinction Will Decide the Next Decade of Patents
January 29, 2024
-
PRISMA 2020 in Practice: Five Things Most Systematic Reviews Still Get Wrong
January 22, 2024
-
Biomarkers Are Not Drug Targets, and Why That Distinction Costs the Industry Billions
January 15, 2024